Spero Therapeutics (SPRO) Net Shares Issued and Repurchased (2017 - 2026)

Spero Therapeutics (SPRO) has reported Net Shares Issued and Repurchased for 10 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Net Shares Issued and Repurchased rose 556.81% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 556.81% YoY), and the FY2025 full-year result was $414417.0, up 379.94% from the prior year.
• Net Shares Issued and Repurchased climbed to $1.1 million in Q1 2026 per SPRO's latest filing, from $414417.0 in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $1.8 million in Q4 2022 and bottomed at $35604.0 in Q1 2024.
• Historically, Net Shares Issued and Repurchased has averaged $644002.9 across 5 years, with a median of $414417.0 in 2025.
• The sharpest annual moves came in 2023 and 2026: Net Shares Issued and Repurchased tumbled 95.13% in 2023, then jumped 556.81% in 2026.
• Over 5 years, Net Shares Issued and Repurchased stood at $1.8 million in 2022, then sank by 35.99% to $1.2 million in 2023, then sank by 92.56% to $86348.0 in 2024, then surged by 379.94% to $414417.0 in 2025, then soared by 169.86% to $1.1 million in 2026.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $1.1 million, $414417.0, and $170271.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.